

NEULAND LABORATORIES LIMITED

Registered Office : Sanali Info Park, 'A' Block, Ground Floor, 8-2-120/113, Road No. 2, Banjara Hills, Hyderabad - 500034



PART - I

Amount in ₹ Million

Sl. No.	Particulars	Quarter Ended 31.12.2013 (Unaudited)	Quarter Ended 30.09.2013 (Unaudited)	Quarter Ended 31.12.2012 (Unaudited)	Nine Months Ended 31.12.2013 (Unaudited)	Nine Months Ended 31.12.2012 (Unaudited)	Year Ended 31.03.2013 (Audited)
1	Income from Operations						
	(a) Net Sales / Income from Operations						
	Exports	934.02	815.24	844.64	2,683.94	2,627.11	3,323.09
	Domestic	374.26	227.61	220.80	880.37	882.60	1,282.77
	Total	1,308.28	1,042.85	1,065.44	3,564.31	3,509.71	4,605.86
	(b) Other Operating Income	7.20	8.12	8.59	22.53	24.77	33.18
	Total Income from Operations (Net)	1,315.48	1,050.97	1,074.03	3,586.84	3,534.48	4,639.04
2	Expenses						
	(a) Consumption of Raw Materials	648.41	582.11	612.14	1,865.81	2,127.17	2,726.06
	(b) Changes in inventories of finished goods and work in process	31.37	(41.79)	(32.88)	36.15	(60.76)	(34.50)
	(c) Employee Benefit Expense	82.79	89.15	80.54	268.29	251.55	348.83
	(d) Depreciation	36.75	37.10	36.96	110.37	110.57	146.22
	(e) Manufacturing Expenses	137.01	116.58	113.28	352.95	333.41	458.45
	(f) Other Expenses	222.58	142.07	111.74	479.24	360.42	493.29
	Total Expenses	1,158.91	925.22	921.78	3,112.81	3,122.36	4,138.35
3	Profit from Operations before Foreign Exchange (gain) / loss and Finance Costs (1-2)	156.57	125.75	152.25	474.03	412.12	500.69
4	Foreign Exchange (gain) / loss (Net)	0.13	15.98	12.65	38.34	37.17	32.46
5	Profit from Operations before Finance Costs (3-4)	156.44	109.77	139.60	435.69	374.95	468.23
6	Finance Costs	59.52	63.06	90.19	181.59	248.36	313.30
7	Profit / (Loss) before Tax (5-6)	96.92	46.71	49.41	254.10	126.59	154.93
8	Tax Expense						
	(a) Current tax	20.79	10.77	8.83	52.61	24.35	30.19
	(b) Deferred Tax	28.69	12.28	7.85	73.33	7.85	41.87
	(c) MAT Credit entitlement	(20.79)	(10.77)	-	(52.61)	-	(53.50)
9	Net Profit / (Loss) for the period (7-8)	68.23	34.43	32.73	180.77	94.39	136.37
10	Paid-up Equity Share Capital (Face Value ₹10 per share)	77.16	77.16	77.16	77.16	77.16	77.16
11	Reserves excluding Revaluation Reserve as per balance sheet of previous accounting year						898.33
12	Earnings per Share (EPS) (in ₹)						
	(a) Basic	8.92	4.50	4.28	23.65	12.35	17.84
	(b) Diluted	8.92	4.50	4.28	23.63	12.34	17.82

PART - II

Sl. No.	Particulars	Quarter Ended 31.12.2013 (Unaudited)	Quarter Ended 30.09.2013 (Unaudited)	Quarter Ended 31.12.2012 (Unaudited)	Nine Months Ended 31.12.2013 (Unaudited)	Nine Months Ended 31.12.2012 (Unaudited)	Year Ended 31.03.2013 (Audited)
A	PARTICULARS OF SHARE HOLDING						
1	Public Shareholding						
	(a) Number of Shares	3,817,199	3,817,199	3,817,199	3,817,199	3,817,199	3,817,199
	(b) Percentage of Shareholding	49.93%	49.93%	49.93%	49.93%	49.93%	49.93%
2	Promoters and Promoter Group Shareholding						
	(a) Pledged / Encumbered						
	-Number of Shares	200,000	200,000	200,000	200,000	200,000	200,000
	-Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	5.22%	5.22%	5.22%	5.22%	5.22%	5.22%
	-Percentage of Shares (as a % of the total share capital of the Company)	2.62%	2.62%	2.62%	2.62%	2.62%	2.62%
	(b) Non-encumbered						
	-Number of Shares	3,627,779	3,627,779	3,627,779	3,627,779	3,627,779	3,627,779
	-Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	94.78%	94.78%	94.78%	94.78%	94.78%	94.78%
	-Percentage of Shares (as a % of the total share capital of the Company)	47.45%	47.45%	47.45%	47.45%	47.45%	47.45%

B INVESTOR COMPLIANTS

Particulars	Quarter Ended 31.12.2013
Pending at the beginning of the quarter	0
Received during the quarter	7
Disposed off during the quarter	7
Remaining unresolved at the end of the quarter	0

NOTES:

- The above unaudited financial results which have been subjected to a limited review by statutory auditors, were reviewed by the Audit Committee at its meeting held on February 4, 2014, and approved and taken on record at the Board of Directors meeting held on February 5, 2014.
- EPS for the quarters and nine months is not annualised.
- The Company's operations are predominantly related to the manufacture of Active Pharmaceutical Ingredients (API). As such there is only one primary reportable segment as per Accounting Standard - AS 17 "Segment Reporting".
- The Board had on January 21, 2014, issued and allotted 10,700 fully paid up equity shares of a face value of Rs.10 each, to eligible employees pursuant to exercise of stock options granted under Employee Stock Option Scheme, 2008.
- The Board of Directors of the Company at their meeting held on February 5, 2014 accorded consent to a rights issue of equity shares not exceeding Rs.25 crores. The Board had also constituted a Rights issue committee to finalise the rights ratio, issue price, record date and other procedural modalities relating to the proposed rights issue.
- Previous quarter / year figures have been regrouped wherever necessary.

**By Order of the Board
For Neuland Laboratories Limited**

Sd/-
Dr. D.R.Rao
Chairman & Managing Director

Place: Hyderabad
Date: February 5, 2014